EGFR and TROP2 are extensively co-expressed in many solid tumors, allowing dual targeting them with bsADCs. DM001 bsADCs simultaneous targeting both EGFR and TROP2 showed superior efficacy compared with parental single-targeting ADCs in PDX models. The new topoisomerase I inhibitor linker/paylopad (BLD1102) exhibits excellent hydrophilicity and is highly stable in human, monkey, and mouse plasmas and in vivo in mice. BLD1102 has strong bystander killing effect. DM001 (DM001-BLD1102) demonstrated superior anti-tumor activity to DM001-vcM MAE in PDX models, including in MMAE-resistant models. DM001 (DM001-BLD1102) inhibited the growth of NSCLC PDX models with or with out EGFR mutations, as well as growth of TNBC, HNSCC, CRC, ESCC and GC PDXs. Pilot safety study of DM001 (DM001-BLD1102) did not show general toxicities in cynomolgus monkeys. Further study is planned.